

# Reza Khosravan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4397960/publications.pdf>

Version: 2024-02-01

15  
papers

612  
citations

932766

10  
h-index

996533

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

644  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 621-634.	1.1	3
2	Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 343-352.	0.6	2
3	Population pharmacokinetics and pharmacodynamics of sunitinib in pediatric patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 181-192.	1.1	7
4	Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. <i>AAPS Journal</i> , 2020, 22, 31.	2.2	11
5	Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 41-50.	1.1	18
6	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245.	1.2	37
7	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269.	1.6	29
8	A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status. <i>Journal of Clinical Oncology</i> , 2012, 30, 363-363.	0.8	9
9	Metabolism and Excretion of [ <sup>14</sup> C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 189-201.	1.0	51
10	Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 57-64.	1.1	19
11	Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 472-481.	1.0	66
12	Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 355-363.	1.1	67
13	Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2006, 45, 821-841.	1.6	85
14	The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 88-102.	1.0	68
15	Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment. <i>American Journal of Therapeutics</i> , 2005, 12, 22-34.	0.5	140